← Eichor
Study identifier: NCT01535430 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Assessment of Eloquent Function in Brain Tumor Patients

Condition: Primary Brain Tumor · Metastatic Brain Tumor  ·  Sponsor: University of Nebraska

PhaseN/A
Planned participants75
Who can joinAll sexes, 19 Years to no upper limit
Healthy volunteersNo

About this study

Purpose of the study: AIM 1: Prospectively collect pre-operative \[functional magnetic resonance imaging (fMRI), diffusion tensor imaging (DTI), magnetoencephalography (MEG)\] and intra-operative mapping data in patients with intra-axial brain tumors to assess how well each modality predicts the location of eloquent brain function. In addition, each modality will be compared with the other. AIM 2: Assess reorganization of eloquent brain function and plasticity in patients with intra-axial brain tumors. This will be accomplished by prospectively collecting post-operative mapping studies and neuropsychological tests to compare them to prior mapping studies as stated above.

This description comes directly from the study's public registry record.

Talk to the study team

Dulce Maroni, PhD  ·  402-836-9751  ·  dmaroni@unmc.edu

Katie Maire, MS  ·  402-559-6895  ·  kmaire@unmc.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of Nebraska Medical CenterOmaha, Nebraska, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT01535430